ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AGY Allergy Therapeutics Plc

2.85
0.00 (0.00%)
Last Updated: 08:00:15
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.85 2.70 3.00 2.85 2.80 2.85 0.00 08:00:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 59.59M -43.07M -0.0090 -3.17 135.84M
Allergy Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 2.85p. Over the last year, Allergy Therapeutics shares have traded in a share price range of 0.85p to 3.80p.

Allergy Therapeutics currently has 4,766,439,938 shares in issue. The market capitalisation of Allergy Therapeutics is £135.84 million. Allergy Therapeutics has a price to earnings ratio (PE ratio) of -3.17.

Allergy Therapeutics Share Discussion Threads

Showing 3251 to 3274 of 5000 messages
Chat Pages: Latest  140  139  138  137  136  135  134  133  132  131  130  129  Older
DateSubjectAuthorDiscuss
29/9/2016
18:14
From elsewhere on the web

Allergy Therapeutics plc 198.6% Potential Upside Indicated by Panmure Gordon

by: Amilia Stone 26th September 2016

Allergy Therapeutics plc using EPIC/TICKER code LON:AGY has had its stock rating noted as ‘Retains’; with the recommendation being set at ‘BUY’ this morning by analysts at Panmure Gordon. Allergy Therapeutics plc are listed in the Health Care sector within AIM. Panmure Gordon have set their target price at 53 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 198.6% from today’s opening price of 17.75 GBX. Over the last 30 and 90 trading days the company share price has decreased 1.35 points and decreased 1.3 points respectively.


Allergy Therapeutics plc LON:AGY has a 50 day moving average of 19.03 GBX and a 200 day moving average of GBX. The 1 year high for the stock price is 34.82 GBX while the 52 week low for the stock is 17.29 GBX. There are currently 601,432,778 shares in issue with the average daily volume traded being 252,540. Market capitalisation for LON:AGY is £106,934,752 GBP.



Allergy Therapeutics plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company’s business segments are Central Europe, Southern Europe, the United Kingdom and Rest of World.

jimmyloser
28/9/2016
15:03
Proactive Investors is here:
sophiegb
28/9/2016
07:08
Perfect news this morning and that should act as the stimulus we need.

This may help too..........From another board.

From Citywire:

"Allergy Therapeutics trading at a significant discount: buy

Allergy Therapeutics (AGY) is trading at a discount to peers and additional upside is in the pipeline.

Numis analyst Paul Cuddon retained his ‘buy’ recommendation and target price of 37p on the shares, which fell 5.4% to 17.4p yesterday.

‘Revenue growth of 19% on constant currency reflects Allergy Therapeutics’ strong performance in Europe, and in our opinion more than compensates for the setback in US development,’ he said.

‘We continue to see a strong outlook for the business in Europe and following the disappointing commercial performance of daily tables in the US, ultimately see it as the best-placed company to crack the larger US market, with a treatment format that suits the US allergists’ preference for injections.

‘The shares trade at a material discount to peers with significant additional upside from the pipeline, which now includes a promising peanut vaccine.’ "

jimmyloser
27/9/2016
14:13
Allergy Therapeutics CEO Manuel Llobet will be presenting to investors at the Proactive One2One Healthcare investor forum on the 6th October in Mayfair. For further details and registration please click here:
aim_trader
27/9/2016
11:21
Morning - new films for Allergy. Results film and re-edited Overview film

www.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/

oshy92
26/9/2016
17:30
I have been traveling all day but see another fall in the price. May I ask if the 17.38 were in fact Buy trades and not a reported sell trades? Any update appreciated.

AGY have certainly got some people they have upset judging by the sheer volume of shares that have materialised - a holdings notice coming?

Nice one Manuel buying a hundred k

The are two lots of two words that will change everything here impo.
The first pair are PROGRESS /USA and the second pair are SUCCESS/USA.

My money certainly looks safe tonight but the Cadillac et al will have wait until they RNS those two words.

lol

impo/dyor

jimmyloser
26/9/2016
07:15
Well these results are a bit better than I expected. They have a solid financial platform on which to pursue the US opportunity. Hopefully this may spark some recovery in the share price but it being AIM you never know!
audigger
23/9/2016
16:21
Well I had a small top-up ahead of Monday. Not expecting any fireworks just some solid numbers for Europe and reassurance that the US opportunity for grass allergy is still huge despite the delay. Would be good to get some further insight in to the peanut opportunity.
audigger
23/9/2016
10:30
I thought that, as I know that they are presenting on the 6th of October and they wouldn't do that in front of this large and high profile audience if they didn't have something to say.
I plan to attend that and then decide even if I have to pay more.

I too am surprised at the flatness

jimmyloser
23/9/2016
09:27
All flat pre-results. I'm thinking I may have a little top-up today....
audigger
21/9/2016
10:05
Overhang now being cleared ahead of Monday????

We will see if we get a tick.

lol

jimmyloser
16/8/2016
16:06
Just how much 'hang' is in an overhang?
jimmyloser
10/8/2016
16:20
Am I alone in being amazed at the constant support for AGY with over 100 buy trades in the last week or so and no movement.
Whatever volume was dropped it must have been significant.

Nice to see the level of confidence and with euro/pound where it is. It is no wonder!

September 26th.

jimmyloser
04/8/2016
19:08
My failure comment was a question. The only failure in a long time here is the mega important dose trialling. The one that truly mattered.
Of course they can right the ship with multiple lines of opportunity in their portfolio but they need to be seen to deliver them.

I shall most likely attend that meeting in London on October 6th.

HOLD for me at the moment as the risks here are currently balanced with opportunity.....just.

impo/dyor.

jimmyloser
04/8/2016
18:50
A bit of institutional off-loading. I think AGY are a million miles away from failure. Biology has a habit of being unpredictable. Your previous post from email correspondence with Manuel was, in my view, reassuring with respect to the issue of dose selection. Things will take longer but so be it. In the meantime they are profitable in Europe and continue to grow market share. And best of all they are investing in other opportunities with peanut allergy. At 18p they are very cheap when balanced against their future business aspirations. I will continue to add on that basis and hope that one day I can retire early on the proceeds! If that doesn't happen then I will have to hope my RBS share holding comes good.....fat chance of that!
audigger
04/8/2016
18:16
That is some overhang that they are shifting.!!! Another 750,000 through tonight.

Are there more still to come - is it the price of failure?

jimmyloser
31/7/2016
17:28
Conjecture corner:
It looks to me as if we have had a million sell shares moved through the market and what a great job the mm's did. I suppose that IC rec was manner from heaven for them.
Did someone get pretty hacked off that a company as safe as AGY could fail on the dosing trial.
I would be interested to know just how much that failure costs us and how much another trial will cost.
Thankfully the base business is doing well enough to carry that very upsetting news and the pound is in the right area now for them.

impo/dyor

jimmyloser
27/7/2016
06:20
Nice one Maddox, I couldn't get to this last year but will make an effort.
jimmyloser
26/7/2016
22:51
Hi Guys,

I've just spotted that AGY are presenting at Proactive Investors One2One Investor Forum in London:

Allergy Therapeutics plc | Cello Group plc | Sphere Medical Holding PLC | ValiRx Plc

Oct 6th 2016, 6.00 pm - Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair

[...]

It's free to attend and I've booked my place. It's the opportunity to talk to the management that I really appreciate.

Cheers Maddox

maddox
26/7/2016
17:29
I figure that we had a large overhang which went through yesterday and cleared this morning. They dropped the bid while they cleared the last of the overhang.

impo.

jimmyloser
26/7/2016
10:33
Unless they are sells? Think of it as a buying opportunity!
audigger
25/7/2016
18:55
Can any of our regulars (or anyone else)offer a view as to what on earth is going on here? Hundreds of thousands bought Friday and To-day and then 'kerplunk' they drop the price!
jimmyloser
22/7/2016
18:57
Yorkie,
Thank you. I thought it was something like that.

jimmyloser
22/7/2016
18:08
Buy recommendation in IC today.
yorkiemike
Chat Pages: Latest  140  139  138  137  136  135  134  133  132  131  130  129  Older

Your Recent History

Delayed Upgrade Clock